A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

Oral squamous cell carcinoma (OSCC) is a leading cause of cancer-related deaths, and early detection is key to improving ...

The incidence of pancreatic adenocarcinoma increases across all age groups, whereas colorectal adenocarcinoma increases only among younger age groups.

The global non-small cell lung carcinoma market is poised for significant expansion over the next decade, according to new industry projections. Valued at USD 8.25 billion in 2023, the NSCLC market is ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

The abstracts will be available on the ASCO® website on May 22, 2025 at 5:00 p.m. ET. The full presentation will be available on the Merus website at the start of the session.

This paper investigates how isoform II of transcription factor RUNX2 promotes cell survival and proliferation in oral squamous cell carcinoma cell lines. The authors used gain and loss of function ...

Reasonably, authors should adapt the title and the abstract in a way that it recapitulates the whole data, which is HOXA1/RNUX2/PRDX2 axis control of cell death, including ferroptosis and apoptosis in ...

The University of Hong Kong, Hong Kong, Hong Kong. Search for other works by this author on: ...

researchers delivered 7.7 to 22.3 times more of the drug inside cancer cells, making the treatment up to 23 times more potent than before, according to the study published April 17 in Cell.

Veterinarians performed the innovative treatment on a 4-year-old Henkel's leaf-tailed gecko, a species at the fringes of zoo ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma ... alone. In 2021, Ferris and colleagues ...